文献速递肿瘤 PET/CT核素与放射性配体治疗

基线18F-flotufolastat PET参数对转移性去势抵抗性前列腺癌177Lu标记PSMA靶向放射性配体治疗结局的预后评估

Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-23

该回顾性分析纳入188例接受[177Lu]Lu-PSMA-I&T治疗的mCRPC患者,评估基线18F-flotufolastat PET参数与PSA反应、PSA-PFS和OS的关系。结果显示基于SUV的指标(如全身SUVmax)是短期结局的显著正向预后因素,而基于体积的指标(如TTV)是长期OS的显著负向预后因素。

要点

  • 全身SUVmax对数和既往化疗是PSA反应及PSA-PFS的显著预后参数。
  • 病灶数目、TTV和ITLV对数是OS的显著预后因素,TTV对数在多变量分析中仍显著。
  • SUV指标与短期结局相关,体积指标与长期OS相关。

核心结论

  • 基线基于SUV的18F-flotufolastat PET指标(如全身SUVmax)是接受[177Lu]Lu-PSMA-I&T治疗的mCRPC患者短期结局(PSA反应和PSA-PFS)的显著正向预后因素;基于体积的指标(如TTV)是长期结局(OS)的显著负向预后因素。

研究设计与样本

  • 回顾性分析,共纳入188例有基线18F-flotufolastat PET扫描的mCRPC患者,肿瘤病灶经半自动勾画,获取基于体积和基于SUV的影像参数。
  • 结局指标包括PSA反应、PSA-PFS和OS;采用单变量和多变量回归分析评估基线影像及治疗前临床参数对结局的影响;事件时间分布用Kaplan-Meier法估计,组间比较用log-rank检验。

主要发现

  • PSA反应和PSA-PFS的显著预后参数包括:对数转换的全身SUVmax(OR 3.26,95%CI 2.01-5.55;HR 0.51,95%CI 0.4-0.66;均p<0.001)和既往化疗(OR 0.3,95%CI 0.12-0.72;HR 1.64,95%CI 1.07-2.58;p=0.008和p=0.028)。
  • OS的显著预后因素包括对数转换的病灶数目(HR 1.38,95%CI 1.24-1.53;p<0.001)、TTV(HR 1.27,95%CI 1.18-1.37;p<0.001)和ITLV(HR 1.24,95%CI 1.16-1.33;p<0.001)。
  • 多变量分析中,对数转换的TTV(HR 1.15,95%CI 1.04-1.27;p=0.008)仍为OS的显著预后因素。

关键数值与推荐

  • PSA反应:对数转换全身SUVmax的OR 3.26(95%CI 2.01-5.55,p<0.001);既往化疗的OR 0.3(95%CI 0.12-0.72,p=0.008)。
  • PSA-PFS:对数转换全身SUVmax的HR 0.51(95%CI 0.4-0.66,p<0.001);既往化疗的HR 1.64(95%CI 1.07-2.58,p=0.028)。
  • OS单变量:对数转换病灶数目的HR 1.38(95%CI 1.24-1.53,p<0.001);对数转换TTV的HR 1.27(95%CI 1.18-1.37,p<0.001);对数转换ITLV的HR 1.24(95%CI 1.16-1.33,p<0.001)。
  • OS多变量:对数转换TTV的HR 1.15(95%CI 1.04-1.27,p=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This retrospective analysis evaluates baseline 18F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [177Lu]Lu-PSMA-I&T. METHODS: A total of 188 mCRPC patients with baseline 18F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics. Outcome measures included prostate-specific antigen (PSA) response, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Univariate and multivariate regression analyses assessed the impact of baseline imaging and pretherapeutic clinical parameters on outcome. Event time distributions were estimated with the Kaplan-Meier method, and groups were compared with log-rank tests. RESULTS: Significant prognostic parameters for PSA response and PSA-PFS included log-transformed whole-body SUVmax (odds ratio (OR), 3.26, 95% confidence interval (CI), 2.01-5.55 and hazard ratio (HR), 0.51, 95% CI, 0.4-0.66; both p < 0.001) and prior chemotherapy (OR 0.3, 95% CI, 0.12-0.72 and HR 1.64, 95% CI, 1.07-2.58; p = 0.008 and p = 0.028, respectively). For OS, significant prognosticators were the following log-transformed parameters: number of lesions (HR 1.38, 95% CI, 1.24-1.53; p < 0.001), TTV (HR 1.27, 95% CI, 1.18-1.37; p < 0.001), and ITLV (HR 1.24, 95% CI, 1.16-1.33; p < 0.001), with log-transformed TTV (HR 1.15, 95% CI, 1.04-1.27; p = 0.008) remaining significant in multivariate analysis. CONCLUSION: At baseline, SUV-based 18F-flotufolastat PET metrics (e.g., whole-body SUVmax) serve as significant positive prognosticators for short-term outcomes (PSA response and PSA-PFS). In contrast, volume-based metrics (e.g., TTV) are significant negative prognosticators for long-term outcome (OS), in mCRPC patients treated with [177Lu]Lu-PSMA-I&T.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Karimzadeh A, Hansen K, Hasa E, et al. Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39847077. doi:10.1007/s00259-024-07003-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。